Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1Phase 1/2 1

Status

Terminated 2Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 13Other hematologic neoplasm 7Plasma cell 6Thoracic 4Other solid neoplasm 4Gastrointestinal 4Dermatologic 2Breast 2Sarcoma 1Myeloid 1Gynecologic 1Genitourinary 1Endocrine 1

Conditions

Solid Tumors 4

Interventions

Cisplatin 70Paclitaxel 68pembrolizumab 65Carboplatin 61Irinotecan 59Injections 53Gemcitabine 53Docetaxel 49Fluorouracil 35Cyclophosphamide 35Pemetrexed 34Oxaliplatin 31Capecitabine 30Bevacizumab 29Leucovorin 27atezolizumab 23Nivolumab 23tislelizumab 19Etoposide 18Cetuximab 17durvalumab 16Temozolomide 16Bortezomib 16alvocidib 15Topotecan 15olaparib 14Sorafenib 14Rifampin 14Itraconazole 14Erlotinib Hydrochloride 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × tocilizumab × Other solid neoplasm × Clear all
NCT03448042 2026-05-28

A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Genentech, Inc.

Phase 1 Active not recruiting
123 enrolled
Other solid neoplasm

Solid Tumors

NCT05129280 2023-08-04

A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors

Hoffmann-La Roche

Phase 1 Terminated
23 enrolled
Other solid neoplasm

Solid Tumors

NCT03539484 2020-09-03

A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors

Hoffmann-La Roche

Phase 1 Terminated
26 enrolled 30 charts
Other solid neoplasm

Solid Tumors

NCT02324257 2020-04-17

A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
149 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡